Table 2.
Changes of the hematological and immunological parameters of control group and other groups treated with oral administration of sofosbuvir and/or its combination with ribavirin in adult male albino rats.
| Parameters | Groups | ||
|---|---|---|---|
| G1 (control group) | G2 (Sofosbuvir ) | G3 (Sofosbuvir + Ribavirin) | |
| Hb concentration g/dL | 12.43 ± 0.6 | 11.67 ± 0.57−a | 10.25 ± 0.79−a−b |
| PCV % | 40.54 ± 1.39 | 34.3 ± 2.43−a | 30.7 ± 2.85−a−b |
| RBCs 106/µl | 7.23 ± 0.54 | 7.61 ± 0.58 | 6.32 ± 0.87−a−b |
| MCV | 51.36 ± 3.6 | 46.53 ± 2.806 | 48.53 ± 4.116 |
| MCH pg/cell | 21.67 ± 3.6 | 16.82 ± 1.529a− | 16.20 ± 0.7642a− |
| RDW-CV% | 22.22 ± 1.6 | 27.48 ± 1.820a+ | 27.83 ± 2.578a+ |
| WBCs 103/µl | 8.63 ± 0.81 | 9.29 ± 0.84 | 7.2 ± 0.48−a−b |
| Platelets 103/µl | 914.3 ± 61.81 | 815.5 ± 40.53−a | 615.3 ± 64.99−a−b |
| Neutrophil % | 23.4 ± 1.6 | 29.9 ± 2.8+a | 18.7 ± 2.2−a−b |
| Lymphocytes % | 72.7 ± 1.98 | 61 ± 3.96−a | 71 ± 2.31+b |
| Monocytes % | 2.43 ± 0.53 | 6.7 ± 3.04+a | 8.29 ± 1.38+a |
| Eosinophil % | 1.43 ± 0.53 | 1.71 ± 0.49 | 1.86 ± 0.38 |
| Basophil % | 0.0 ± 0.0 | 0.71 ± 0.49+a | 0.14 ± 0.38−b |
The results presented Mean ± S.D. of seven rats.
asignificantly different from control group at (p < 0. 05).
bsignificantly different from G2 (Sofosbuvir group) at (p < 0. 05).